Drug Profile
AVE 9488
Latest Information Update: 03 Jul 2007
Price :
$50
*
At a glance
- Originator OSI Pharmaceuticals
- Class
- Mechanism of Action Nitric oxide synthase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Angina pectoris; Heart failure
Most Recent Events
- 03 Jul 2007 Discontinued - Phase-I for Angina pectoris in USA (unspecified route)
- 03 Jul 2007 Discontinued - Phase-I for Congestive heart failure in USA (unspecified route)
- 01 Mar 2005 Phase-I clinical trials in Angina pectoris in USA (unspecified route)